Losmapimod

Zusammenfassung

Losmapimod ist ein neuartiger Wirkstoff gegen kardiovaskuläre Erkrankungen, der zurzeit in klinischen Studien getestet wird. Der Wirkmechanismus beruht auf einer Hemmung von p38 MAP-Kinasen, welche eine wichtige Rolle bei der Entwicklung von Atherosklerose und ischämisch bedingter Herzinsuffizienz spielen. Tierexperimentelle Daten weisen auf einen protektiven Effekt durch pharmakologische p38-Hemmung hinsichtlich kardiovaskulärer Erkrankungen hin. Dieser Artikel beurteilt das therapeutische Potential dieses neuen pharmakologischen Wirkprinzips und bewertet die aktuelle klinische Studienlage zu Losmapimod.

Abstract

Losmapimod is a promising new agent against cardiovascular diseases. This drug works by inhibiting p38 MAP kinases, which play an important role in the development of atherosclerosis and heart failure caused by ischemic conditions. Preclinical data from in vitro and in vivo studies suggest a protective role of pharmacological p38 inhibition with regard to the development of cardiovascular diseases. This article evaluates the therapeutic potential of this new pharmacological approach and discusses the current clinical data on Losmapimod.

Schlüsselwörter

Losmapimod - p38 MAPK - kardiovaskuläre Erkrankungen - Atherosklerose - Herzinsuffizienz - Remodeling

Keywords

Losmapimod - p38 MAPK - cardiovascular diseases - atherosclerosis - heart failure - remodeling

• Literatur

• 1 Aston NM, Bamborough P, Buckton JB et al. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. J Med Chem 2009; 52: 6257-6269
• 2 Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale Versorgungsleitlinie Chronische Herzinsuffizienz. . Version 1.5 März 2012
• 3 Cheriyan J, Webb AJ, Sarov-Blat L et al. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 2011; 123: 515-523
• 4 Clark JE, Sarafraz N, Marber MS. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacol Ther 2007; 116: 192-206
• 5 Elkhawad M, Rudd JH, Sarov-Blat L et al. Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis. JACC Cardiovasc Imaging 2012; 5: 911-922
• 6 Enbrel®. Fachinformation. Pfizer Pharma GmbH. Stand Juli 2012.
• 7 Genovese MC. Inhibition of p38: has the fat lady sung?. Arthritis Rheum 2009; 60: 317-320
• 8 Ju H, Behm DJ, Nerurkar S et al. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther 2003; 307: 932-938
• 9 Kaiser RA, Lyons JM, Duffy JY et al. Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2005; 289: H2747-H2751
• 10 Kardakaris R, Gareus R, Xanthoulea S et al. Endothelial and macrophage-specific deficiency of P38α MAPK does not affect the pathogenesis of atherosclerosis in ApoE-/- mice. PLoS One 2011; 6: e21055
• 11 Kerkela R, Force T. p38 mitogen-activated protein kinase: a future target for heart failure therapy?. J Am Coll Cardiol 2006; 48: 556-558
• 12 Kumphune S, Chattipakorn S, Chattipakorn N. Role of p38 inhibition in cardiac ischemia/reperfusion injury. Eur J Clin Pharmacol 2012; 68: 513-524
• 13 Kwon HJ, Coté TR, Cuffe MS et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-811
• 14 Lomas DA, Lipson DA, Miller BE et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 2012; 52: 416-424
• 15 Marber MS, Rose B, Wang Y. The p38 mitogen-activated protein kinase pathway-a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol 2011; 51: 485-490
• 16 Mei S, Gu H, Ward A et al. p38 Mitogen-activated Protein Kinase (MAPK) Promotes Cholesterol Ester Accumulation in Macrophages through Inhibition of Macroautophagy. J Biol Chem 2012; 287: 11761-11768
• 17 Olzinski AR, McCafferty TA, Zhao SQ. Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection. Cardiovasc Res 2005; 66: 170-178
• 18 Remicade®. Fachinformation. MSD Sharp & Dohme GmbH. Stand März 2012.
• 19 Seeger FH, Sedding D, Langheinrich AC et al. Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression. Basic Res Cardiol 2010; 105: 389-397
• 20 Statistisches Bundesamt. Diagnosedaten der Patienten und Patientinnen in Krankenhäusern . (einschl. Sterbe- und Stundenfälle) – Fachserie 12 Reihe 6.2.1 – 2010.
• 21 US National Institutes of Health. Clinical trials. http://www.clinicaltrials.gov/ct2/results?term=GW856553 Letzter Zugriff 30.10.2012.
• 22 WHO. Cardiovascular diseases (CVDs). Fact sheet No 317. September 2012. http://www.who.int/mediacentre/factsheets/fs317/en/index.html Letzter Zugriff 30.10.2012.
• 23 Willette RN, Eybye ME, Olzinski AR et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. J Pharmacol Exp Ther 2009; 330: 964-970